title: Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
abstract: The standard of care for transitional-cell carcinoma of the bladder with invasion to the muscularis propria is radical cystectomy with bilateral pelvic lymph node dissection. However, currently there is a tendency for organ preservation in selected cases of muscle-invasive bladder cancer. Trimodality treatment, including transurethral resection of the bladder tumor (TURBT), radiation therapy and chemotherapy, has been shown to produce 5-year and 10-year overall survival rates comparable to those of radical cystectomy. The current 5-year overall survival rates range from 50 to 67% with trimodality treatment, and approximately 75% of the surviving patients maintains their bladder. After trimodality treatment complete response is obtained in more than 70% of patients with muscle-invasive bladder cancer. Clinical criteria helpful in determining patients for bladder preservation include such variables as small tumor size (<2 cm), early tumor stage (T2-T3 disease), a visibly and microscopically complete TURBT, absence of ureteral obstruction, no evidence of pelvic lymph node metastases, and absence of carcinoma in situ (Tis). The close collaboration of urologists, radiation oncologists and medical oncologists is of paramount importance in succeeding in bladder preservation.
authors.affiliation: Servicio de Oncología, Hospital de Torrejón, Calle Mateo Inurria, s/n, Torrejón de Ardoz, 28850 Madrid, Spain. drkhosravi@hotmail.com
authors.forename: Parham
authors.initials: P
authors.lastname: Khosravi-Shahi
authors.forename: Luis
authors.initials: L
authors.lastname: Cabezón-Gutiérrez
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D019042:Muscle Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D009361:Neoplasm Invasiveness; D059351:Organ Sparing Treatments / Q000379:methods*; D018579:Patient Selection; D011788:Quality of Life; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome; D001743:Urinary Bladder; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin